These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 6779079)

  • 1. [Chagas disease and immunosuppression].
    Barousse AP; Costa JA; Eposto M; Laplume H; Segura EL
    Medicina (B Aires); 1980; 40 Suppl 1():17-26. PubMed ID: 6779079
    [No Abstract]   [Full Text] [Related]  

  • 2. [Cutaneous involvement in systemic Chagas disease in immunocompromised patient].
    Canese A; Di Martino Ortiz B; González Burgos L; Centurión MÉ
    Med Clin (Barc); 2012 May; 138(14):e27. PubMed ID: 22093407
    [No Abstract]   [Full Text] [Related]  

  • 3. [Trypanosoma cruzi high parasitemia in patient with systemic lupus erythematosus].
    dos Santos-Neto LL; Polcheira MF; Castro C; Lima RA; Simaan CK; Corrêa-Lima FA
    Rev Soc Bras Med Trop; 2003; 36(5):613-5. PubMed ID: 14576877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kidney transplantation and Chagas' disease. A two-year follow-up of a patient with parasitemia.
    Lopez-Blanco OA; Cavalli NH; Jasovich A; Gonzalez-Cappa S; Nadal MA; Boschi A; Argüello EA; Stamboulian D; Favaloro R; Gotlieb D
    Transplantation; 1983 Aug; 36(2):211-3. PubMed ID: 6410558
    [No Abstract]   [Full Text] [Related]  

  • 5. Reactivation of Chagas disease by immunosuppressive therapy in a patient with systemic lupus erythematosus: report of an exceptional case.
    Burgos LG; Ortiz BD; Canese A; Ojeda A; Melo M
    Am J Dermatopathol; 2012 Aug; 34(6):e84-9. PubMed ID: 22814327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Longitudinal study of the persistence of the therapeutic action of nifurtimox and benznidazole in patients with chronic chagas infection].
    Schenone H; Rojas A; Alfaro E; Concha L; Aranda R
    Bol Chil Parasitol; 1981; 36(3-4):59-62. PubMed ID: 6812600
    [No Abstract]   [Full Text] [Related]  

  • 7. [Dynamic studies of skin microcirculation during treatment of lupus nephritis with cytostatic immunosuppressants].
    Mach ES; Solov'ev SK; Ivanova MM
    Ter Arkh; 1980; 52(6):113-6. PubMed ID: 7404376
    [No Abstract]   [Full Text] [Related]  

  • 8. [Cytostatics in the treatment of lupous disease].
    Stroescu O; Ciobanu V; Răileanu I; Suţeanu S; Mihăilescu E; Berceanu S
    Med Interna (Bucur); 1967 Jul; 19(7):845-58. PubMed ID: 6052171
    [No Abstract]   [Full Text] [Related]  

  • 9. Successful treatment with posaconazole of a patient with chronic Chagas disease and systemic lupus erythematosus.
    Pinazo MJ; Espinosa G; Gállego M; López-Chejade PL; Urbina JA; Gascón J
    Am J Trop Med Hyg; 2010 Apr; 82(4):583-7. PubMed ID: 20348503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Indications for the so-called immunosuppressive therapy. With special reference to the diffuse connective tissue diseases].
    Messini M; Guglielmi G; Ciavarelli F; Messini R
    Clin Ter; 1969 Jan; 48(2):105-44. PubMed ID: 5404642
    [No Abstract]   [Full Text] [Related]  

  • 11. Chronic intracellular protozoan infections and kidney transplantation.
    González Cappa SM; López Blanco OA; Müller LA; Cavalli NH; Niño RF; Freilij H
    Transplantation; 1991 Aug; 52(2):377-80. PubMed ID: 1908149
    [No Abstract]   [Full Text] [Related]  

  • 12. [Nifurtimox treatment of chronic Chagasic infection in children].
    Schenone H; Contreras M; Solari A; García A; Rojas A; Lorca M
    Rev Med Chil; 2003 Sep; 131(9):1089-90. PubMed ID: 14635599
    [No Abstract]   [Full Text] [Related]  

  • 13. [Reversibility of the uremic syndrome during a course of lupus kidney disease].
    Vercellone A; Stratta P; Camussi G; Dogliani M; Caramello E; Paola M
    Minerva Nefrol; 1976; 23(1):53-68. PubMed ID: 995331
    [No Abstract]   [Full Text] [Related]  

  • 14. Value of the lymphocyte nucleolar parameters for the estimation of therapy effectiveness in chronic diseases with immune lymphocyte involvement.
    Micu D; Mihăilescu E; Sighetea E; Olinescu V; Constantineanu I
    Med Interne; 1979; 17(3):285-91. PubMed ID: 583079
    [No Abstract]   [Full Text] [Related]  

  • 15. [Hair changes in immunosuppressive therapy].
    Kostanecki W; Mazurkiewicz W; Górkiewicz A; Zborzil J
    Z Haut Geschlechtskr; 1971 Oct; 46(19):704-8. PubMed ID: 5137252
    [No Abstract]   [Full Text] [Related]  

  • 16. [Chagas disease and immunosuppression].
    Barousse AP
    Medicina (B Aires); 1980; 40(6 Pt 2):896. PubMed ID: 6783808
    [No Abstract]   [Full Text] [Related]  

  • 17. [Part VI. Antiparasitic treatment for Chagas disease].
    B WA; G IH; L MI; M LJ; V PM; H IN; V AM; P JS; H MT; A IZ
    Rev Chilena Infectol; 2008 Oct; 25(5):384-9, discussion 387. PubMed ID: 18949153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of cognitive dysfunction in patients with systemic lupus erythematosus.
    McLaurin EY; Holliday SL; Williams P; Brey RL
    Neurology; 2005 Jan; 64(2):297-303. PubMed ID: 15668428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of systemic lupus erythematosus with L-asparaginase: considerations on a case].
    Pastor EM; Jamra M; Verrastro Almeida T; Saldanha RV; de Paula e Silva P; Kedor H; Serro A; de LG
    Rev Hosp Clin Fac Med Sao Paulo; 1972; 27(3):129-33. PubMed ID: 5038988
    [No Abstract]   [Full Text] [Related]  

  • 20. [Disputable problems of immunosuppressive therapy with cytostatic drugs].
    Berliner GB
    Klin Med (Mosk); 1976 Jun; 54(6):134-8. PubMed ID: 972505
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.